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Abstract  
 
Objective(s) 
Previous studies have demonstrated that pretreatment with alpha-tocotrienol (α-TCT) can reduce ischemic 
damage in mice following middle cerebral artery (MCA) occlusion. It is also reported to decrease stroke-
dependent brain tissue damage in 12-Lox-deficient mice and spontaneously hypertensive rats. In the present 
study, the neuroprotective effects of α-TCT and rosiglitazone (RGZ) at 3 hr after cerebral ischemia were 
investigated.  
Materials and Methods 
Stroke was induced by embolizing a preformed clot into the MCA. Rats were assigned to vehicle, α-TCT            
(1 or 10 mg/kg), RGZ and sham-operation.  
Results 
Compared to the control group, only RGZ decreased infarct volume (P<0.05), neurological deficits (P<0.05) 
and sensory impairments (P<0.01) but low and high doses of α-TCT did not show any significant 
neuroprotective effect.  
Conclusion 
Our data showed that α-TCT was not neuroprotective at 3 hr after the embolic model of stroke. Further 
studies should be undertaken to clarify the neuroprotective effects of α-TCT after stroke. 
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Introduction 
Despite several advantages in stroke care and 
therapy, only a small number of acute stroke 
patients (3%) receive specific therapy (1). 
Sustained attempts to increase this percentage 
include the extension of the 3 hr time window 
for intravenous thrombolysis (2). In addition to 
vessel recanalizing strategies, research has 
focused on the introduction of neuroprotective 
pharmacological therapies. Potential 
neuroprotective drugs were evaluated in clinical 
trials but except thrombolysis therapy, no 
successful candidates could be identified (3). 
Several concomitant factors have likely 
contributed to these failures, including poor 
preclinical pharmacodynamic evaluations, 
especially narrow treatment windows. 
Evaluation of long-term recovery in both 
permanent and transient focal stroke models, 
improves patient selection criteria and trial 
design based on the preclinical modeling (4). 
As suggested by STAIR (Stroke Therapy 
Academic Industry Roundtable), the efficacy 
of a new neuroprotective drug should be 
demonstrated in a variety of stroke models 
performed in different species and by different 
laboratories. Outcome measures should 
include both infarct size and behavioral 
assessments, with attention to the therapeutic 
time window in relationship to the time period 
of penumbral survival in the models being 
used (5).  
Clinical and experimental findings have 
suggested that free radical-induced lipid 
peroxidation is an important factor in the 
pathogenesis of ischemic brain damage (6). 
Various natural antioxidants are present in 
cerebral tissue, of which the lipid-soluble 
nutrient vitamin E scavenges lipid peroxyl 
radicals and thereby inhibits lipid 
peroxidation. However, during ischemia and 
subsequent reperfusion, because of an 
overwhelming production of radicals, natural 
antioxidants cannot suppress the radicals. In 
these  circumstances,  administration  of           
Alpha-tocotrienol (α-TCT) have been shown 
to reduce ischemic damage in mice by middle 
cerebral artery (MCA) occlusion (7) or stroke-
dependent brain tissue damage in 12-Lox-
deficient mice and spontaneously hypertensive 
rats (8). It has been suggested that at 
micromolar concentrations, α-TCT protects 
neural cells by virtue of its antioxidant 
property and at nanomolar concentrations; it 
prevents neurodegeneration by regulating 
specific signaling processes involved in (9). In 
the studies that reported the neuroprotective 
effects of  α-TCT, functional outcomes were 
not investigated and the drug administered 
only before or immediately after ischemia (7, 
8). Although functional outcome does not 
always correlate with infarct size, it is the 
measure used in clinical trials of 
neuroprotective agents (10). Due to delayed 
hospitalization, even in recent clinical trials, 
fewer than 2% of patients received study agent 
within 2 hr of onset of event (11). The purpose 
of this study is to examine the neuroprotective 
effects of α-TCT at 3 hr after cerebral 
ischemia induced by embolic model of stroke 
in rats.  The embolic model has been used 
previously in different experiments to induce 
experimental stroke in rodents. This model 
mimics human stroke and is more relevant to 
the pathophysiological situation in patients. To 
the best of our knowledge, neither the long-
term beneficial effects of α-TCT on ischemic 
damage nor its effects on functional outcomes 
after embolic stroke have been examined. 
 
Materials and Methods 
All procedures used in this study were carried 
out in accordance with the Prevention of 
Cruelty to Animals Act 1986 under the 
guidelines of the NH and MRC Code of 
Practice for the Care and Use of Animals for 
Experimental Purposes in Australia. Adult 
male  hooded  wistar  rats  weighting  300  to          
350 g were maintained on a 12 hr light/dark 
cycle with food and water available ad libitum.  
Eight animals were used in each group. Rats 
were assigned to vehicle (Dimethylsulfoxide, 
DMSO),  α-TCT (1 or 10 mg/kg) (100%; 
Carotech Selangor, Malaysia), rosiglitazone 
(RGZ; Alexis biochemicals, Lausanne, 
Switzerland) and sham-operation. α-TCT and  
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RGZ (3 mg/kg) were dissolved in DMSO and 
sterile 0.9% saline (up to 10% v/v) and 
injected (ip) 3 hr after the middle cerebral 
artery (MCA) embolization. 
 
Focal embolic stroke model 
Clot formation 
One day before ischemic onset, arterial blood 
was withdrawn from donor rats into PE-50 
tubes, stored at room temperature for 2 hr, and 
then kept at 4 ºC for 22 hr. 
 
Physiological parameters monitoring 
Rats  were  anesthetized  with  isoflurane           
(5% induction and 2% maintenance) (Aerrane, 
Fort Dodge, IA, USA). Body temperature was 
maintained normothermic (37 
oC) by using a 
heating pad placed under the animal, and 
temperature was monitored by means of a 
rectal temperature probe. Arterial blood 
samples were obtained via the catheter placed 
in the tail artery, for continuous blood pressure 
monitoring. A blood gas, oximetry, electrolyte 
and metabolic system machine (Radiometer 
Medical A/S, Copenhagen, Denmark) was 
used to monitor arterial PaO2, PaCO2,  pH and 
glucose. Blood was analyzed exactly 5 min 
before and after embolization. 
 
Cerebral blood flow monitoring 
Relative regional cerebral blood flow was 
monitored  with  laser  Doppler  monitor       
(LD-CBF). A coronal incision was made 
across the scalp, the temporalis muscle was 
reflected and a burr hole (1 mm posterior to 
the bregma and just lateral to the linea 
temporalis) was created (12). The Doppler 
probe was placed extradurally. The Doppler 
probes were fixed to the burr holes with a 2 
mm cranial bolt (Integra Scientific) to 
eliminate motion and ensure stability. 
Recordings were taken at a frequency of 2 Hz 
for a minimum of 10 min prior to 
embolization, continuously throughout the 
surgery and for a minimum of 5 min after clot 
injection. According to the method described 
by Dinapoli et al (2006), accurate laser 
Doppler placement over the MCA perfusion 
area was verified by pinching temporarily the 
common carotid artery, before induction of the 
stroke (12).  
Focal cerebral ischemia 
The focal cerebral ischemia was induced by 
embolizing a preformed clot into the MCA as 
reported previously (12, 13). A longitudinal 
incision of 1.5 cm in length was made in the 
midline of the ventral cervical skin. The right 
common carotid artery, right internal carotid 
artery, and right external carotid artery were 
exposed. The distal portion of the external 
carotid artery was ligated and cut. Coagulated 
blood was subsequently sectioned into 20 mm 
segments, washed with saline and transferred 
to a modified PE-50 catheter with a tip 
diameter of 0.3 mm for injection. The 
modified  PE-50  tube  with  the  20  mm  clot          
(5 µl) was connected to a 50 µl Hamilton lock 
syringe, and advanced 19 mm in the internal 
carotid artery until its tip was away from the 
origin of the MCA. The preformed clot was 
then injected, and the catheter was removed. A 
minimum initial reduction of 70% in the laser 
Doppler reading was considered a successful 
occlusion of middle cerebral artery perfusion 
territory (12). Animals without 70% reduction 
in the laser Doppler reading, were deemed to 
have had failed successful clot placement and 
were excluded from any further study. For 
sham-operated animals, 5 µl saline was 
injected. The wound was closed and the 
animal returned to its cage. The duration of 
surgery did not exceed 30 min in any case. 
 
Measurement of infarct volumes  
The quantification of infarct volume has been 
previously described in detail (12, 13). All 
animals were sacrificed 48 hr after the onset of 
MCA occlusion. The brains were removed 
from the skull, freezed at -70 ºC for 5 min and 
using a brain matrix sliced into 2 mm 
intervals. A total of 6 coronal sections were 
collected,  and  the  sections  were  stained              
with a 2% 2, 3, 5- triphenyltetrazolum chloride 
solution (Sigma, UK) at 37 ºC and fixed by 
immersion in a 10% phosphate-buffered 
formalin solution. The stained brain sections 
were placed directly on the scanning screen of 
a color flatbed scanner (Canon, Japan). The  
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person who analyzed the images was unaware 
of the treatments animals received, using a 
commercial image processing software 
program. The total volume of each hemisphere 
and infarction was determined by integration 
of the distance of the 6 sections. The infarct 
volume was calculated with the following 
formula: 
Infarct volume= [volume of left hemisphere- 
(volume of right hemisphere-measured infarct 
volume)]/volume of left hemisphere]. 
 
Evaluation of behavior 
Neurological deficits were recorded before 
embolization and 2, 24 and 48 hr after it. Any 
animal with neurological sign before studying 
was removed from the study. Neurological 
deficits were determined with a modified 6-
point scale (14) as follow: 0, no observable 
deficit; 1, forelimb flexion; 2, forelimb flexion 
plus decreased resistance to lateral push; 3, 
unidirectional circling; 4, unidirectional 
circling plus decreased level of consciousness; 
5, no spontaneous walking and lying in the 
cage on left side or death. For evaluation of 
sensory impairment, the adhesive removal test 
was used (15). All rats were trained for the 
adhesive removal test daily for 3 days before 
MCA embolization. Then the animals were 
tested before surgery and 24 and 48 hr post-
operatively. During the adhesive removal test, 
one piece of an adhesive paper (10×5 mm
2) 
was placed on the left distal radial regions of 
forelimb as a tactile stimulus. The time it takes 
the rat to touch and remove each stimulus from 
the limb was recorded during 3 trials and 
averaged. Rats with impaired sensory function 
allow the paper to stay on the forelimb for 
longer periods of time. An observer blind to 
the experimental groups carried out all 
behavioral analysis. 
 
Measurement of α-TCT concentration in the 
brain 
To verify whether α-TCT crosses the blood 
brain barrier and reaches the ischemic area by 
ip injecting (1 or 10 mg/kg), its concentration 
in the cerebellum of the animals were 
measured at 24 and 48 hr after stroke by 
HPLC as described before (16). The Waters 
Alliance 2695 Separations Module connected 
with a guard cartridge (Jour Guard C18) to an 
analytical column. Detection: Model 2475 
fluorescence detector. Stationary phase: C18 
stationary phase coupled with 
spectrophotometric and fluorometric detection. 
Mobile phase: acetonitrile–methanol (65:35 by 
volume), and the flow rate was 1 ml/min.   
(n=3 for α-TCT at 24 hr, n=3 for α-TCT at 48 
hr, and n=2 for control group at 48 hr). 
Cerebellums of the animals were extracted as 
reported previously (17). 
 
Statistical Analysis 
Infarct volumes, α-TCT concentrations, 
sensory impairments and physiological 
parameters are presented as mean±SEM and 
analyzed with one-way ANOVA followed by 
Tukey’s test. Neurological deficits are reported 
as  medians  and  interquartile  ranges  (25  th         
and 75 th percentiles) and was analyzed with 
Kruskal-Wallis test. Differences were 
considered significant when P< 0.05. 
 
Results 
We did not observe any infarction, 
neurological deficits or sensory impairment in 
the sham-operated animals. 
 
Evaluation of physiological parameters 
during surgery 
Physiological parameters including blood 
gases, pH, heart rate, blood glucose and 
arterial blood pressure were determined during 
the surgery. The results are shown in Table 1. 
There was no difference between groups 
considering these parameters. 
 
 
Effect of α-TCT and RGZ on infarct volume 
Embolization of a preformed clot resulted in an 
infarction in the ipsilateral hemisphere, mainly 
located in the middle cerebral artery irrigated 
region. The effect of α-TCT (1 and 10 mg/kg, ip) 
administration on cerebral ischemia onset was 
determined and compared with control and RGZ 
(3 mg/kg, ip). RGZ is an agonist of the nuclear 
receptor and transcription factor peroxisome  
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proliferator-activated receptors (PPAR)-γ that 
has been decreased infarct volume and 
neurological deficits in human (18) and animal 
stroke models (19, 20). The results are shown in 
Figure 1.  
 
Table  1.  Comparison  of  physiological  parameters  at        
5 min before or after embolic stroke in different groups.  
 
 
Physiological parameters were measured at 5 min 
before or after embolic stroke. Data are presented as 
mean±SEM. The groups were DMSO (0.1 ml/kg, as 
control), rosiglitazone (RGZ) (3 mg/kg) and alpha-
tocotrienol (α-TCT). N=6 in the α-TCT group (3 
animals in each dose of 1 and 10 mg/kg) and n=5 in the 
other groups. ِ     Differences between the groups were not 
significant. *MAP: Mean arterial pressure. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Effect of α-TCT (alpha-tocotrienol) and RGZ 
(rosiglitazone) on infarct volume at 3 hr after stroke. 
The groups were control (DMSO 0.1 ml/kg), (RGZ             
3 mg/kg) and α-TCT (1 or 10 mg/kg). One-way 
ANOVA followed by the Tukey-test revealed that 
infarct volume in RGZ treated group was significantly 
different from the control group (P<0.05). Data are 
presented as means±SEM. *P<0.05 compared to the 
control group. N=8 in each group.   
 
The infarct volume 48 hr after the embolic 
injury for the control, RGZ, low and high 
doses of α-TCT groups were 29.42±2.61%, 
15.87±3.1%, 24.86±2.14%, and 28.97±4.79%, 
respectively. Compared to the control group, 
only RGZ decreased infarct volume by 46% 
(P<0.05) but low and high doses of α-TCT did 
not show any significant neuroprotective 
effect.  
 
Evaluation of behavior 
In this part of experiments, neurological 
deficits and sensory impairments were 
recorded before, and 2, 24 and 48 hr after 
embolization. Changes of neurological deficits 
scores in different groups are shown in Table 
2. Compared to the control group, α-TCT with 
low and high doses did not improve 
neurological deficits when administered 3 hr 
after embolic stroke. Administration of RGZ 3 
hr after MCA embolization decreased 
neurological deficits at 48 hr after embolic 
stroke (P<0.05). The effects of two doses of α-
TCT and RGZ on sensory impairment are 
showed in Figure 2. While RGZ treated 
animals removed sticky tabs from their 
affected forelimb more quickly than control 
group (P<0.01) at 24 hr and 48 hr after stroke, 
neither doses of α-TCT did not show any 
significant effect.   
 
Table 2. Comparison of neurological deficits scores in 
different groups. 
                Control               α-TCT1         α-TCT10         RGZ 
2 hr        3 (2-4) 
 n=8 
3 (2-3) 
n=7 
3 (3-4) 
n=8 
3 (2-3.75) 
n=8 
24 hr      3 (2-4) 
 n=7 
3 (2-4) 
n=7 
3 (3-5) 
n=6 
2 (2-2) 
n=7 
48 hr       3 (3-4) 
  n=6 
4 (2-4)
 
n=6 
4 (2-5) 
n=6 
1.5 (1-2)* 
n=7 
 
Neurological deficits were determined at 2, 24 and 48 hr 
after the embolic stroke. Data are expressed as medians 
and interquartile ranges; 25th and 75th percentiles are 
shown in the parentheses. The drugs studied were 
DMSO (0.1 ml/kg, as control), rosiglitazone             
(RGZ, 3 mg/kg), α-TCT (alpha-tocotrienol) 1 or 10 
mg/kg. *P<0.05 compared to the control group.  
 
 
Measurement of α-TCT concentration in the 
cerebellum of animals 
For verifying whether α-TCT crosses the blood 
brain barrier and delivers the ischemic area by ip 
injecting, its concentration in the cerebellum of 
the animals were measured as described in the 
method section. Concentration of α-TCT in the 
cerebellum of α-TCT treated (10 mg/kg) rats at 
24 and 48 hr after stroke and the control group at 
48 hr were determined. 
 
Variables  Control  α-TCT  RGZ 
Glucose            Before: 
(mg/dl)             After: 
220±14 
214±18 
216±19 
218±13 
214±19 
215±17 
pH                    Before: 
                         After: 
7.37±0.02 
7.41±0.02 
7.40±0.02 
7.39±0.03 
7.412±0.03 
4.42±0.04 
PO2                   Before: 
(mmHg)            After: 
95±8 
100±3 
94±9 
97±4 
98±6 
101±3 
PCO2                Before: 
(mmHg)            After: 
35.5±1.4 
38.3±0.7 
34.2±1.2 
35.3±1.5 
33.8±1.5 
32.9±1.9 
*MAP              Before: 
(mmHg)           After: 
91±4 
94±3 
95±6 
90±7 
93±3 
92±5 
Heart rate         Before: 
(beats/min.)      After: 
362±34 
352±42 
358±46 
368±40 
380±34 
367±43 
*
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Figure 2. Effect of α-TCT (alpha-tocotrienol) and RGZ 
(rosiglitazone) administration on sensory impairment 
(latency in removing the adhesive paper) at 3 hr after 
stroke.  The  groups  were  control  (DMSO  0.1  ml/kg),           
α-TCT (1 or 10 mg/kg) and RGZ (3 mg/kg). One-way 
ANOVA followed by the Tukey-test revealed that 
sensory impairment in RGZ treated group was 
significantly decreased when compared to the control 
group at 24 and 48 hr after stroke (P<0.01). Data are 
presented as means±SEM. * P<0.05 compared to the 
control group. n=6 for α-TCT (10 mg/kg) and n=7 for 
the other groups at 24 hr after stroke. n=7 for RGZ                   
and =6 for the remaining groups at 48 hr after stroke. 
 
 
 
The  α-TCT concentrations are expressed in 
Figure 3. One-way ANOVA followed by the 
Tukey-test revealed that concentration of α-TCT 
in the drug treated animals at 24 hr after 
embolization was significantly higher than the 
control group (P<0.01). 
 
*
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Figure 3. Concentration of α-TCT (mg/l) in the 
cerebellum of animals at 24 or 48 hr after stroke when 
the drug injected 3 hr after embolic cerebral ischemia. 
In the control group, concentration of α-TCT was 
determined at 48 hr after stroke. α-TCT concentration in 
the control (n=2), 24 hr (n=3) or 48 hr (n=3) group after 
stroke were 0.087±0.001, 0.91±0.055, and 0.466±0.14, 
respectively. One-way ANOVA followed by the Tukey-
test revealed that concentration of α-TCT in the drug 
treated animals at 24 hr after embolization           
significantly was different from the control group. 
*P<0.01 compared to the control group.  
Discussion 
In the present study, we examined the 
neuroprotective effect of α-TCT, on ischemic 
brain injury using experimental embolic stroke 
model in rat. The natural vitamin E family 
includes eight chemically distinct molecules: 
α-, β-, γ- and δ-tocopherol; and α-, β-, γ- and 
δ-tocotrienol. Tocochromanols contain a polar 
chromanol head group with a long isoprenoid 
side chain. Depending on the nature of the 
isoprenoid chain, tocopherols (containing a 
phytyl chain) or tocotrienols (geranylgeranyl 
chain) can be distinguished (21). 
Our results did not show any decrease in 
infarct volume, neurological deficits or 
sensory impairments by administering either 
low or high doses of α-TCT (1 or 10 mg/kg) at 
3 hr after cerebral ischemic onset. On the other 
hand, thiazolidinedione RGZ (3 mg/kg) an 
agonist of the nuclear receptor and 
transcription factor peroxisome proliferator-
activated receptors γ (PPAR-γ) significantly 
decreased the infarct volume and improved the 
functional outcomes when administered at the 
same time.  PPAR-γ activation enhances 
insulin sensitivity and reduces serum glucose 
in diabetic patients without significant 
alterations in serum glucose of non-diabetic 
animals or humans (22) and its 
neuroprotection have been well documented. 
For example, it has recently been reported that 
thiazolidinediones as the agonists of PPAR-γ, 
decreased infarct volume and neurological 
deficits following transient (23), permanent 
(24) and embolic (19) models of stroke.   
Glutamate toxicity is a major contributor to 
neurodegeneration after stroke. It includes 
excitotoxicity and an oxidative stress 
component also known as oxytosis (25). It has 
been suggested that α-TCT is the most potent 
neuroprotective form of vitamin E in 
glutamate-induced degeneration of HT4 
hippocampal neurons (26). At nanomolar 
concentrations,  α-TCT  in  contrast  to                   
α-tocopherol, protected against glutamate-
induced neuronal death by suppressing 
inducible pp60 csrc kinase activation (26) and 
inducible 12- lipoxygenase activation (8).   
These effects of tocotrienol were independent 
of antioxidant property (26). Moreover, when 
injected immediately after stroke, α-TCT  
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decreased the size of the cerebral infarcts 1 day 
after stroke   while γ-TCT and δ-TCT did not (7).  
The above reported findings urged us to 
investigate neuroprotective effects of α-TCT 3 hr 
after embolic stroke because in none of the 
previous reports long-term beneficial effects of 
α-TCT had been studied. The main aim in stroke 
studies is finding a potential drug with a wider 
protection because treatment of stroke often does 
not begin until several hr after the initial insult. 
One reason that why our results are not 
consistent with the other investigators may be 
due to the time of administration. Indeed, the 
failure of many clinical trials is likely due to the 
short treatment window in which the compounds 
can be administered (27). Therefore, gone are 
the days when drugs that confer neuroprotection 
when given before or a short period after 
cerebral ischemia can be considered relevant for 
therapy of ischemic stroke. 
The length of time during which 
neuroprotectants can be expected to be 
effective is likely to vary from drug to drug 
and depends on an individual drug's specific 
mechanism of action. Glutamate-induced 
toxicity is a very early event during the acute 
phase of ischemic stroke, which means that 
glutamate antagonists are likely to be effective 
as neuroprotectants for only a short time 
(perhaps as little as 1 to 2 hr) (28). Therefore, 
at the time that we injected α-TCT (3 hr after 
stroke), neurotoxic cascades of glutamate 
might have been happened and so this 
compound was not protective.  
Oxygen free radicals cause destruction of 
cellular membranes. Accordingly, the free 
oxygen radical scavengers might have a 
potential neuroprotective role. So, we expected 
that α-TCT might be neuroprotective through 
its radical scavenging properties as well as two 
radical scavenger citicoline and NXY-059 
which has been shown that they have 
neuroprotective effects. Preclinical studies in 
animal stroke models showed that citicoline, a 
radical scavenger, improved neurological 
outcome and infarct size when used 
immediately after stroke. However, the clinical 
phase III trials with varying dosing schedules 
did not show efficacy (29). NXY-059 is a 
nitrone-based free-radical-trapping agent 
which has been proven to reduce the infarct 
size in the transient and permanent MCA 
occlusion rat stroke models when administered 
up to 8 hr after onset of ischemia.  It was also 
shown to improve the neurologic outcome 
(measured by performance scores) 3 weeks 
and 10 weeks after the stroke, and to reduce 
the infarct size in a marmoset stroke model 
when  administration  was  delayed  for  up  to           
4 hr after stroke onset. A safety trial tested 
NXY-059 in stroke patients and this agent was 
found to be safe in doses that were 
neuroprotective in the animal models (29, 30).     
The reason why our results are not consistent 
with the above studies and α-TCT did not 
show neuroprotective effects through its 
radical scavenging properties is uncertain. 
Perhaps antioxidative effect of α-TCT is not as 
high as citicoline and NXY-059, or different 
models of stroke may play a role which 
remains to be determined in future. 
We thought that the drug with ip injection 
might not be delivered to the brain. Therefore, 
the α-TCT concentration were measured in the 
cerebellum of some animals and we have 
observed that ip injection resulted in 
significant delivery of α-TCT to the brain and 
at 24 hr after injecting, its level was increased 
even to 10 times of the base level (Figure 3). 
Recently, it has been suggested that the safe 
dose of various tocotrienols for human 
consumption is 200–1000 mg/d (31). 
Therefore, the doses used in current study 
were enough to show the potential 
neuroprotection. 
Based on our results and the reports of other 
investigators (25-27), α-TCT might be 
remaining as a good neuroprotective when 
administered only before predictable cerebral 
ischemia. Although the failure of α-TCT 
seems to be a major limitation in the present 
study, this natural form of vitamin E cannot be 
countered by a clinically relevant 
administration because long-term beneficial 
effects of brain protective therapies have been 
recommended as the endpoint of experimental 
stroke studies as well as clinical stroke studies 
(5).  
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Conclusion 
Our data showed that α-TCT was not 
neuroprotective at 3 hr after the embolic model 
of cerebral ischemia. Further studies should be 
undertaken to optimize the treatment regimen 
and to clarify the neuroprotective  effects  of    
α-TCT after stroke. 
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